Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

The introduction thoroughly reviews the ANGPTL protein family, the differential regulation of LPL by ANGPTL3/8 versus ANGPTL3/4, genetic studies of ANGPTL3 and ANGPTL8 loss-of-function variants, and the limitations of existing therapies such as evinacumab, vupanorsen, and zodasiran. The rationale for developing a specific anti-ANGPTL3/8 antibody is logically built from these observations. The limitations of prior research (e.g., HDL-C lowering with ANGPTL3 inhibition, lesser LDL-C reduction with ASO/siRNA approaches) are explicitly acknowledged.

The study is described as 'randomized, double-blind' with participants allocated 6:2 to active or placebo within each cohort, which addresses randomization_method, randomization_unit, and blinding_levels adequately. Inclusion/exclusion criteria are explicitly listed (age 18-65, BMI 18.5-40, triglycerides 135-499 mg/dL, LDL-C ≥70 mg/dL). A pre-planned safety review before dose escalation was conducted. Power_analysis is not reported, which is acceptable for a phase 1 first-in-human study where the primary endpoint is safety. Blinding levels are adequately described as double-blind with placebo control, which is the field standard for this type of trial. Outlier handling is defined: 'Log-transformed values outside three standard deviations of the mean were considered outliers and excluded from the dataset.' Controls are the matched placebo group within each cohort. Independent_replication is not applicable as this is a first-in-human study.

Sex is reported: 36 men and 12 women (75% male). Age, BMI, and key lipid parameters are reported in Table 1. As this is a human clinical study, species_strain_source and housing_conditions are not applicable. Demographics are reported in Table 1 including age, sex, and BMI. The study includes both sexes, so the 'sex_justified' criterion is not applicable. Age is reported as median (min, max) per group. Health status is addressed by the inclusion criteria ('overtly healthy').

The trial was approved by the institutional review board or ethics committee at each site. Informed consent was obtained from participants. Compliance with the Declaration of Helsinki and ICH Good Clinical Practice is stated. A protocol number (J1T-MC-GZEA) is provided. The clinical trial is registered at ClinicalTrials.gov (NCT04052594). The ethics bodies are not named individually, which is common for multicenter trials but the statement is adequate as per the guidelines. Informed consent is explicitly stated. Regulatory compliance is named (Declaration of Helsinki, ICH-GCP).

The investigational product LY3475766 is named with its mechanism and preclinical development described. The placebo is identified (0.9% sodium chloride). No antibodies, cell lines, or wet-lab reagents are used in the clinical portion; these bench criteria are not applicable. Software tools are identified: Phoenix WinNonlin version 8.1 for noncompartmental pharmacokinetic analysis, and SAS version 9.4 for statistical analysis. Reagents_identified is scored against the investigational product, which is named with formulation (subcutaneous/intravenous) and dose, but no lot number or additional manufacturing details are provided — this is adequate for a phase 1 trial.

Tests named: mixed model for repeated measures, Pearson correlation, power model for dose proportionality. Assumptions: normality assumption is indirectly addressed via log-transformation for skewed data, but explicit normality/equal variance tests for the mixed model are not reported; however, the model-based approach accommodates this. Exact p-values are not provided in the main text; instead, least-squares mean changes with standard errors are the primary reporting format. Pearson correlation p-values are reported to four decimal places. Effect sizes with confidence intervals are reported for the dose-proportionality analysis (Cmax ratio 6.9, 90% CI 2.9-16.3). Data presentation: Figures 1-5 show individual-group means with error bars (s.e.) over time, and n per group is stated. Mathematical plausibility: The reported percentages (e.g., 75% male, triglyceride reductions) are plausible given the sample sizes. No arithmetic errors were detected in the reviewed data.

Methods completeness: The protocol and SAP are provided in the supplementary materials, and methods sections are detailed enough for replication. Trial registration: NCT04052594 is provided in the abstract and methods. Reporting guideline: A 'Reporting Summary' is linked, suggesting adherence to a guideline, but it is not explicitly named (e.g., CONSORT). All_outcomes_reported: All pre-specified outcomes (safety, PK, PD) are reported, with negative results (e.g., modest/no changes for ApoA-I, ApoA-II) included. Limitations_discussed: The discussion mentions limitations including the single-dose design, the need for multiple-ascending-dose studies, the impact of COVID-19 on enrollment, and the lack of cardiovascular outcome data. Conclusions_proportional: The conclusions are appropriately cautious (e.g., 'the effects on cardiovascular risk remain to be established'). Funding_coi: Funding from Eli Lilly is stated, and detailed competing interests are provided for all authors.